- Home
- INVH vs IKT Comparison
INVH vs IKT Comparison
Compare INVH & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVH
- IKT
- Stock Information
- Founded
- INVH 2012
- IKT 2008
- Country
- INVH United States
- IKT United States
- Employees
- INVH N/A
- IKT N/A
- Industry
- INVH Real Estate
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- INVH Finance
- IKT Health Care
- Exchange
- INVH Nasdaq
- IKT Nasdaq
- Market Cap
- INVH 20.9B
- IKT 159.2M
- IPO Year
- INVH 2017
- IKT 2020
- Fundamental
- Price
- INVH $32.26
- IKT $3.42
- Analyst Decision
- INVH Buy
- IKT Strong Buy
- Analyst Count
- INVH 20
- IKT 2
- Target Price
- INVH $38.75
- IKT $6.50
- AVG Volume (30 Days)
- INVH 3.2M
- IKT 450.8K
- Earning Date
- INVH 02-11-2025
- IKT 11-14-2024
- Dividend Yield
- INVH 3.48%
- IKT N/A
- EPS Growth
- INVH N/A
- IKT N/A
- EPS
- INVH 0.72
- IKT N/A
- Revenue
- INVH $2,554,563,000.00
- IKT $1.00
- Revenue This Year
- INVH N/A
- IKT N/A
- Revenue Next Year
- INVH $4.86
- IKT N/A
- P/E Ratio
- INVH $44.77
- IKT N/A
- Revenue Growth
- INVH 7.65
- IKT N/A
- 52 Week Low
- INVH $31.01
- IKT $1.12
- 52 Week High
- INVH $37.80
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- INVH 34.70
- IKT 52.41
- Support Level
- INVH $31.58
- IKT $3.12
- Resistance Level
- INVH $33.63
- IKT $4.20
- Average True Range (ATR)
- INVH 0.56
- IKT 0.42
- MACD
- INVH -0.20
- IKT -0.00
- Stochastic Oscillator
- INVH 16.16
- IKT 30.67
About INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of nearly 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 16 target markets that feature high employment and household formation growth with almost 70% of the portfolio in the Western U.S. and Florida; 15 of the 16 markets featuring average rents lower than homeownership costs.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.